MED3000 for ED: an update

[CanGetItUpButNoMore]

I found this article on MED3000.

https://www.discovermagazine.com/health ... -a-placebo

It describe the history of the product's development. Interestingly, according to the article, it was originally the placebo in the controlled trial of another product. When the placebo performed as well as the product, the placebo itself was developed as MED3000.

[frank66665]

I found this article on MED3000.

https://www.discovermagazine.com/health ... -a-placebo

It describe the history of the product's development. Interestingly, according to the article, it was originally the placebo in the controlled trial of another product. When the placebo performed as well as the product, the placebo itself was developed as MED3000.

we have been talking about this drug for years, but in Italy not even the shadow of this drug

[Flavio]

Still waiting.

As always, our Asian friends will kick our a***s and get the drug first.

I strongly suggest you find an Asian forwarder to buy and ship MED3000, once it becomes available in China and other countries. I have a great Chinese forwarder called Oliver Deng.

Here are some of the pharma companies that will commercialise MED3000 in the near future: Labatec Pharma (Middle East), m8 (Brazil and Mexico) and Atlantis (China).

https://www.labatecpharma.com/2021/09/2 ... st-region/

https://www.trinitydelta.org/research-n ... -achieved/

[tonyareias]

Featuring Futura’s DermaSys drug delivery technology, MED3000 is designed to stimulate nerve sensors when applied to the head of the penis, leading to smooth muscle relaxation, tumescence and erection. In the phase 3 study, investigators randomized 96 men clinically diagnosed with mild, moderate or severe erectile dysfunction to use MED3000 or oral tadalafil, the active ingredient in Eli Lilly’s Cialis.

After 24 weeks, Futura saw a statistically significant improvement from baseline in erectile dysfunction, as measured using the International Index of Erectile Function (IIEF-EF) questionnaire, causing the trial to hit one of its co-primary endpoints.

The other co-primary endpoint showed that participants experienced an average change from baseline on the IIEF-EF score of 5.73 units, exceeding the 4-unit difference on which Futura said it agreed with the FDA. MED3000 outperformed tadalafil in terms of speed of onset of action, leading Futura to talk up the prospect of it making a claim such as “helps you get an erection within 10 minutes.”

Futura reported tolerability advantages of MED3000 over tadalafil, such as the reduced frequency of headaches, but in other regards the oral therapy performed better. “Overall tadalafil showed a greater improvement in erectile function than MED3000,” Futura said in a statement.

https://www.fiercepharma.com/pharma/futuras-topical-erectile-dysfunction-therapy-hits-phase-3-goal-igniting-race-fda

[tonyareias]

Futura Medical "on track" for launch in H1 2023

https://newsdirect.com/news/futura-medical-on-track-for-launch-in-h1-2023-321636324

With initial launches planned in the first half of 2023, Futura said it is expanding its network of licensing and distribution partners.

A first production order of Eroxon has been received to enable initial launches through European and UK distribution partner, Cooper Consumer Health, which is said to remain on track.

First production for initial launches in the Middle East are planned for 2023, with an agreement through distribution partner Labatec Pharma.

https://www.proactiveinvestors.co.uk/companies/news/1001025/futura-medical-hails-progress-of-med3000-gel-1001025.html

[Brent1]

I don't hold my breath. The trials are most likely done with very mild ed-cases or psychological e.d.
The cold gel plus the placebo effect will cause an erection by those man. For man with real e.d. this won't work!
With a lot of advertising the company will earn millions out of all the desperate man. Sad, but true...

[Flavio]

I don't hold my breath. The trials are most likely done with very mild ed-cases or psychological e.d.
The cold gel plus the placebo effect will cause an erection by those man. For man with real e.d. this won't work!
With a lot of advertising the company will earn millions out of all the desperate man. Sad, but true...

Let's wait and see!

Even if it's just for mild cases of ED, it is an improvement and will be more than welcome.

[Flavio]

The official website for EROXON (MED3000):

www.eroxon.com

It seems you can sign up to receive updates, check out their email address.

[Flavio]

If you're in Europe, here's another website that may be helpful:

www.cooperconsumerhealth.eu

[Brent1]

It's a scam. I found this article about Med2005, which is basically Med3000.
As you can read the International Index of Erectile Function (IIEF) score is prior usage 17.1 and after 19.6 and 18.5 for placebo. So going from 17.1 to 19.6 for the Med2005 group is also a placebo-like score. A trial for rubbing toothpaste on your penis would basically give the same scores.
The scores for PDE-5 inhibitors in the clinical trials were much higher.

https://scholar.google.com/scholar?hl=n ... BHZt6Oy0EJ


pieces were sung with great recision anlert. 瀾 sometimes when I meet with such apathy on the pur
TTTS TTS SLLLSTTT
JE Roll made a few remarks on the Tonic Sol-fa||..."," J", ought to be active. Mlany of the D. Methol recºmmenline it it is simplicit: il P-||...... was System. One, I ness. The audience appeared highly gratilied witlu tlu know, is doing well. I have lately visited the tttS ikkS:"":""; 點"":"", 1 classes, which are all taught by unprofessional man
Bekijken op search.proquest.com
Verwante artikelen
sciencedirect.com
Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study
David J Ralph, Ian Eardley, Jorg Taubel, Paul Terrill, Tim Holland
The Journal of Sexual Medicine 15 (2), 167-175, 2018
Background
Current treatments for erectile dysfunction (ED) have some limitations.
Aim
This study evaluated the efficacy and tolerability of MED2005, a 0.2% glyceryl trinitrate topical gel, formulated into an enhanced absorption topical delivery system (DermaSys), administered on demand, in the treatment of ED.
Methods
This randomized, double-blinded, placebo-controlled, phase II crossover trial involved 232 men with ED (231 treated, 230 assessed for efficacy) and their partners. After a 4-week run-in period, patients were randomized to 1 of 2 treatment sequences, MED2005-placebo or placebo-MED2005. Each treatment was given for 4 weeks, separated by a 1-week washout interval. Efficacy was assessed by the International Index of Erectile Function (IIEF), the Sexual Encounter Profile, a Global Assessment Questionnaire (GAQ), and specific questions about the onset and offset of action and treatment preferences (patients and partners).
Outcomes
The primary outcome measure was the IIEF erectile function domain (IIEF-EF) score. Other efficacy assessments were secondary outcomes.
Results
The mean baseline IIEF-EF score was 17.1 (SD = 5.7), and this increased to 19.6 (SD = 7.5) after MED2005 treatment and 18.5 (SD = 6.7) after placebo (P = .0132). Overall, 23.1% of patients showed a clinically relevant (≥4-point) increase in IIEF-EF scores after treatment with MED2005 only compared with 14.5% who responded after MED2005 and placebo, 14.0% who responded after placebo only, and 48.4% who did not respond after either treatment (P = .0272). MED2005 also was associated with significant improvements compared with placebo in the other IIEF domains, and this was consistent with patients’ and partners’ responses to the GAQ. For all assessments, significant effects of MED2005 were seen primarily in patients with mild ED. The start of erection was noticed within 5 and 10 minutes in 44.2% and 69.5%, respectively, of all intercourse attempts with MED2005. Patients and partners showed significant preferences for MED2005 over placebo. The most commonly reported adverse events during MED2005 treatment were headache (patients, n = 18 [7.9%]; partners, n = 3 [1.3%]) and nasopharyngitis (patients, n = 13 [5.7%]; partners, n = 2 [0.9%]).
Clinical Implications
These findings suggest that topical glyceryl trinitrate could be a useful treatment option in ED.
Strengths and Limitations
Strengths of this study include the use of a validated outcome measure. Limitations include the use of only 1 dosage.
Conclusion
Further studies are warranted to investigate the efficacy of topical glyceryl trinitrate to include higher doses, thereby improving clinical significance, especially in cases of moderate and severe ED.
Ralph DJ, Eardley I, Taubel J, et al. Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study. J Sex Med 2018;15:167–175.